AU2001294552A1 - Compounds and methods for inhibiting alpha-1 beta-1 integrins - Google Patents

Compounds and methods for inhibiting alpha-1 beta-1 integrins

Info

Publication number
AU2001294552A1
AU2001294552A1 AU2001294552A AU9455201A AU2001294552A1 AU 2001294552 A1 AU2001294552 A1 AU 2001294552A1 AU 2001294552 A AU2001294552 A AU 2001294552A AU 9455201 A AU9455201 A AU 9455201A AU 2001294552 A1 AU2001294552 A1 AU 2001294552A1
Authority
AU
Australia
Prior art keywords
integrins
beta
compounds
methods
inhibiting alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294552A
Inventor
Cezary Marcinkiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of AU2001294552A1 publication Critical patent/AU2001294552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU2001294552A 2000-09-11 2001-09-12 Compounds and methods for inhibiting alpha-1 beta-1 integrins Abandoned AU2001294552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23159100P 2000-09-11 2000-09-11
US60231591 2000-09-11
PCT/US2001/028522 WO2002022571A2 (en) 2000-09-11 2001-09-12 Compounds and methods for inhibiting alpha-1 beta-1 integrins

Publications (1)

Publication Number Publication Date
AU2001294552A1 true AU2001294552A1 (en) 2002-03-26

Family

ID=22869882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294552A Abandoned AU2001294552A1 (en) 2000-09-11 2001-09-12 Compounds and methods for inhibiting alpha-1 beta-1 integrins

Country Status (4)

Country Link
EP (1) EP1322322A4 (en)
AU (1) AU2001294552A1 (en)
CA (1) CA2421786A1 (en)
WO (1) WO2002022571A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016883A2 (en) * 2003-08-14 2005-02-24 Icos Corporation Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2015087334A1 (en) 2013-12-15 2015-06-18 Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. Viperistatin-derived peptides and uses thereof
WO2019018688A1 (en) * 2017-07-20 2019-01-24 The University Of Virginia Patent Foundation Methods for treatment or prevention of a neurological immunity disorder
CN110974938A (en) * 2019-12-02 2020-04-10 上海长海医院 Application of integrin α 1 β 1 inhibitor in preparation of medicines for preventing or treating aortic diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors

Also Published As

Publication number Publication date
EP1322322A2 (en) 2003-07-02
CA2421786A1 (en) 2002-03-21
WO2002022571A3 (en) 2002-06-20
WO2002022571A2 (en) 2002-03-21
EP1322322A4 (en) 2005-04-06

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU5991699A (en) Quinolizinones as integrin inhibitors
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2001295758A1 (en) Seal
AU2002216966A1 (en) Sludge inerting method
AU2001266755A1 (en) Protective seal for cans
AU2002211662A1 (en) Nf-kappab inhibitors
AU2001281633A1 (en) Detection method
AU2001243394A1 (en) Compounds and methods
AU2001234730A1 (en) Method for inhibiting complement activation
AU2001296597A1 (en) Method for absorbing fluid
AU2723099A (en) Tryptase inhibitors
AU2001282062A1 (en) Sealing system
AUPR050700A0 (en) Detection method
AUPQ667800A0 (en) Detection method
AU2000256695A1 (en) Bolt seal
AUPQ872300A0 (en) Compounds and methods
AU3235100A (en) Prothease inhibitors
AU2001294552A1 (en) Compounds and methods for inhibiting alpha-1 beta-1 integrins
AU2001278951A1 (en) Compounds and methods
AU2002220237A1 (en) Roll up door
AUPP979099A0 (en) Ioniser for effluent gas
AU2001268040A1 (en) Methods and compounds for inhibiting mrp1
AU2002235277A1 (en) Compounds and methods